Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

291
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
291
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

260
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
260
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

226
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
226
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

254
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
254
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

2.6K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
2.6K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

85
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
85

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

From human hand joints to continuum robot: how articular surface morphology shapes flexibility and stability in template-based designs.

Bioinspiration & biomimetics·2025
Same author

Automatic pelvic fracture segmentation: a deep learning approach and benchmark dataset.

Frontiers in medicine·2025
Same author

FracFormer: Fracture Reduction Planning With Transformer-Based Shape Restoration and Fracture Data Simulation.

IEEE transactions on medical imaging·2025
Same author

Preoperative fracture reduction planning for image-guided pelvic trauma surgery: A comprehensive pipeline with learning.

Medical image analysis·2025
Same author

Automatic path planning for pelvic fracture reduction with multi-degree-of-freedom.

Computer methods and programs in biomedicine·2025
Same author

Time course of cardiac rupture after acute myocardial infarction and comparison of clinical features of different rupture types.

Frontiers in cardiovascular medicine·2024

相关实验视频

Updated: Sep 14, 2025

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

10.9K

甲状腺功能障碍和肺动脉高血压:一个双向的门德尔随机化研究.

Gongli Pang1, Xiaoxia Wang2, Ru Zhao1

  • 1Department of Cardiology, Shanxi Cardiovascular Hospital, Taiyuan, Shanxi, China.

International journal of cardiology. Heart & vasculature
|July 21, 2025
PubMed
概括

甲状腺功能低下症与肺动脉高血压 (PAH) 的风险增加有关. 这项研究使用门德尔随机化来调查甲状腺功能障碍和PAH之间的关联,没有发现反向因果关系.

关键词:
门德尔的随机化肺动脉高血压是肺动脉高血压.甲状腺功能障碍 甲状腺功能障碍

更多相关视频

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
10:20

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Published on: January 16, 2013

25.4K
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

377

相关实验视频

Last Updated: Sep 14, 2025

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

10.9K
Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
10:20

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Published on: January 16, 2013

25.4K
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

377

科学领域:

  • 心血管医学 心血管医学
  • 内分泌学 在内分泌学.
  • 遗传流行病学遗传流行病学

背景情况:

  • 甲状腺功能障碍与心血管疾病有关.
  • 甲状腺功能障碍与肺动脉高血压 (PAH) 风险增加之间存在潜在的联系.
  • 这种关联的因果性需要调查.

研究的目的:

  • 调查甲状腺功能障碍和PAH之间的因果关系.
  • 使用双向双样本的门德尔随机化 (MR) 分析.

主要方法:

  • 暴露因素包括甲状腺功能障碍标志物 (FT3,FT4,TSH,甲状腺功能过高,甲状腺功能低下).
  • 肺动脉高血压 (PAH) 是结果因素.
  • 使用反向变量权重 (IVW),MR-Egger和权重中位数方法分析了双向因果关系,评估了异质性和性.

主要成果:

  • 甲状腺功能低下症显著增加了PAH风险 (OR = 1.485,P = 0.025).
  • 自由三甲状腺素 (FT3),自由甲状腺素 (FT4),甲状腺激素 (TSH) 和甲状腺功能障碍症与PAH风险没有关联.
  • 没有发现PAH与甲状腺功能障碍的逆因果关系的证据.

结论:

  • 甲状腺功能低下症与肺动脉高血压 (PAH) 的风险增加有关.
  • 需要进一步的研究来阐明甲状腺功能障碍和PAH之间的复杂关系.